Connect to MCP

ClaudeChatGPTClaude Code (CLI)CursorVS Code

Finch Therapeutics Group Valuation Multiples

Finch Therapeutics Group is valued at $17M as of October 2026, a 155.3x revenue multiple. In the last fiscal year, Finch Therapeutics Group revenue was $107K and Finch Therapeutics Group EBITDA was ($78M).

See full Finch Therapeutics Group profile

Finch Therapeutics Group Overview

About Finch Therapeutics Group

Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).

Founded

2017

HQ

United States

Employees

1

Financials (Last FY)

Revenue: $107K
EBITDA: ($78M)

EV

$17M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Finch Therapeutics Group Financials

Finch Therapeutics Group reported last fiscal year revenue of $107K and negative EBITDA of ($78M).

In the same fiscal year, Finch Therapeutics Group generated ($78M) in EBITDA losses and had net loss of ($75M).

Finch Therapeutics Group P&L

In the most recent fiscal year, Finch Therapeutics Group reported revenue of $107K and EBITDA of ($78M).

Finch Therapeutics Group is unprofitable as of last fiscal year, with EBITDA margin of (73145%) and net margin of (69864%).

See analyst estimates for Finch Therapeutics Group
Last FY2023202620272028
Revenue$107K$107K
EBITDA($78M)($78M)
EBITDA Margin(73145%)(73145%)
EBIT Margin(31778%)(31778%)
Net Profit($75M)($75M)
Net Margin(69864%)(69864%)
Net Debt($23M)-

Financial data powered by Morningstar, Inc.

Finch Therapeutics Group Stock Performance

Finch Therapeutics Group has current market cap of $17M, and enterprise value of $17M.

Market Cap Evolution

Finch Therapeutics Group's stock price is $10.35.

Finch Therapeutics Group has an EPS (earnings per share) of $-46.55.

See more trading valuation data for Finch Therapeutics Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$17M$17M0.0%---$-46.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Finch Therapeutics Group Valuation Multiples

Finch Therapeutics Group trades at 155.3x EV/Revenue multiple, and (0.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for Finch Therapeutics Group

Finch Therapeutics Group Financial Valuation Multiples

As of November 8, 2026, Finch Therapeutics Group has market cap of $17M and EV of $17M.

Finch Therapeutics Group has a P/E ratio of (0.2x).

Last FY2023202620272028
EV/Revenue155.3x155.3x
EV/EBITDA(0.2x)(0.2x)
EV/EBIT(0.5x)(0.5x)
P/E(0.2x)(0.2x)
EV/FCF(0.5x)(0.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Finch Therapeutics Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Finch Therapeutics Group Margins & Growth Rates

In the most recent fiscal year, Finch Therapeutics Group reported EBITDA margin of (73145%) and net margin of (69864%).

See estimated margins and future growth rates for Finch Therapeutics Group

Finch Therapeutics Group Margins

Last FY202720282029
EBITDA Margin(73145%)
EBIT Margin(31778%)
Net Margin(69864%)
FCF Margin(29444%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Finch Therapeutics Group Operational KPIs

Finch Therapeutics Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $84.0M for the same period.

Access forward-looking KPIs for Finch Therapeutics Group
Last FY2023202620272028
Revenue per Employee$0.1M-
Opex per Employee$84.0M-
G&A Expenses to Revenue8964%8964%
R&D Expenses to Revenue6728%6728%
Opex to Revenue78475%78475%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Digital TherapeuticsHorizontal MarketplacesInvestment BankingERP SoftwareDeveloper ToolsConsumer SaaSStreamingVertical SaaSNetworking HardwareFinancial Data & InformationEnergy StorageRoad InfrastructureSemiconductors
Explore Valuation Multiples by Industry

Finch Therapeutics Group Competitors

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E

This data is available for Pro users. Sign up to see all Finch Therapeutics Group competitors and their valuation data.

Start Free Trial

Finch Therapeutics Group VC Funding History

Before going public, Finch Therapeutics Group raised $189M in total equity funding, across 5 rounds.

Finch Therapeutics Group Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Sep-20Series DShumway Capital; Octave Group; Humboldt Fund; OMX Ventures; DFO Management; The Baupost Group; Octave Ventures LLC; BDT & MSD Partners; OCV; Susquehanna International Group; Avenir; SymBiosis LLC$90M--
Aug-19Series CShumway Capital; Morgan Noble; Willett Advisors LLC; OCV; Susquehanna International Group; Trans-Pacific Technology Fund (TPTF); Avenir$54M-Finch Therapeutics Group is a clinical-stage microbiome therapeutics company developing Full-Spectrum Microbiota (FSM) and Rationally-Selected Microbiota (RSM) therapies. The company's lead program, CP101, is an oral capsule therapy designed to restore a balanced microbiome and is being evaluated in the PRISM3 clinical trial for the prevention of recurrent Clostridioides difficile infections. CP101 received FDA Breakthrough Therapy designation. Beyond C. difficile, Finch is advancing investigational therapies for autism spectrum disorder (ASD) and inflammatory bowel disease (IBD), with the IBD program developed in partnership with Takeda Pharmaceuticals. In August 2019, Finch completed a Series C financing round of $53 million led by OCV Partners, with participation from new investors Susquehanna International Group (SIG), Symbiosis LLC, and the Trans-Pacific Technology Fund, as well as existing investors Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors. The company used the proceeds to advance its microbiome-based therapeutic pipeline and accelerate clinical development. Prior to the Series C, Finch had raised a Series A of $5.6 million in 2017 and a Series B of $36 million in 2018, accumulating over $184 million in total funding before its eventual March 2021 IPO on the Nasdaq, which raised $128 million.
Mar-18Series BShumway Capital; Morgan Noble; Willett Advisors LLC; Avenir$36M-Finch Therapeutics Group is a clinical-stage microbiome drug development company focused on developing therapeutics based on microbiome science. The company completed a Series B financing of $36 million in March 2018, as reported by VC News Daily on March 5, 2018. The company later raised additional capital, including a $53 million Series C in August 2019 and a $90 million Series D in September 2020, demonstrating continued investor confidence in its microbiome therapeutics platform. Finch Therapeutics subsequently went public via IPO on March 19, 2021.
Jan-17Seedbpd partners$4M--
Dec-16Series A-$6M-Finch Therapeutics Group is a clinical-stage microbiome therapeutics company developing orally delivered products like CP101 to treat recurrent Clostridioides difficile infection and other conditions such as autism spectrum disorder and inflammatory bowel disease. The company, founded in 2014 and based in Somerville, Massachusetts, focuses on Full-Spectrum Microbiota and Rationally-Selected Microbiota therapies to restore balanced microbiomes. A Series A round of $5.6 million occurred on December 1, 2016, led by Flight Partners Management. This was followed by a $36 million oversubscribed Series B in 2017 from investors including Shumway Capital, Willett Advisors, Morgan Noble, and Avenir Growth Capital, bringing total funding to $77 million since launch. Subsequent financings included a $53 million Series C in August 2019 with OCV Partners, Susquehanna International Group, Symbiosis, and others to advance CP101's PRISM3 trial and pipeline expansion.

Acquisitions by Finch Therapeutics Group

Finch Therapeutics Group has acquired 1 company to date.

Last acquisition by Finch Therapeutics Group was on October 23rd 2017. Finch Therapeutics Group acquired Crestovo for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Finch Therapeutics Group

Crestovo
Description
Crestovo is a clinical-stage biopharmaceutical company developing microbiome-based therapies using Full-Spectrum Microbiota derived from healthy human donors. Headquartered in Cambridge, Massachusetts, the firm advances CP101, an oral capsule in Phase 3 trials for recurrent Clostridioides difficile infection via the PRISM-3 study. Building on research from collaborators at Center for Digestive Diseases and University of Minnesota, Crestovo targets gut dysbiosis in inflammatory bowel disease and other conditions. Acquired by Cigna in 2021, it leverages donor screening and lyophilization for scalable production.
HQ CountryUnited States
HQ City
-
Deal Date23 Oct 2017
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Finch Therapeutics Group acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Finch Therapeutics Group

When was Finch Therapeutics Group founded?Finch Therapeutics Group was founded in 2017.
Where is Finch Therapeutics Group headquartered?Finch Therapeutics Group is headquartered in United States.
How many employees does Finch Therapeutics Group have?As of today, Finch Therapeutics Group has over 1 employees.
Is Finch Therapeutics Group publicly listed?Yes, Finch Therapeutics Group is a public company listed on OTCM.
What is the stock symbol of Finch Therapeutics Group?Finch Therapeutics Group trades under FNCHQ ticker.
When did Finch Therapeutics Group go public?Finch Therapeutics Group went public in 2021.
Who are competitors of Finch Therapeutics Group?Finch Therapeutics Group main competitors include
What is the current market cap of Finch Therapeutics Group?Finch Therapeutics Group's current market cap is $17M.
What is the current revenue of Finch Therapeutics Group?Finch Therapeutics Group's last fiscal year revenue is $107K.
What is the current EV/Revenue multiple of Finch Therapeutics Group?Current revenue multiple of Finch Therapeutics Group is 155.3x.
Is Finch Therapeutics Group profitable?No, Finch Therapeutics Group is not profitable.
How many companies Finch Therapeutics Group has acquired to date?As of November 2026, Finch Therapeutics Group has acquired 1 company.
What was the largest acquisition by Finch Therapeutics Group?None of the M&A deals Finch Therapeutics Group has completed have disclosed valuations.
What companies Finch Therapeutics Group acquired?Finch Therapeutics Group acquired Crestovo.
In how many companies Finch Therapeutics Group has invested to date?Finch Therapeutics Group hasn't invested in any companies yet (or none have been disclosed publicly).

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial